FDA pushes review date for Biogen blood drug

Share this article:

FDA extended the review time for Biogen Idec's Alprolix, a candidate for hemophilia B, by three months, the company said today. The biotech added that it submitted “additional information related to the validation of a manufacturing step for Alprolix,” and due to the timing of that submission, the agency extended its PDUFA date to allow more time to review. Hemophilia B is a rare, inherited disorder that impairs the blood's ability to clot. Alprolix is also under review in Canada, Australia and Japan. Biogen Idec also has a long-acting recombinant coagulation factor pending approval for the treatment of hemophilia A. That drug, to be sold under the name Eloctate, was also delayed 90 days; its PDUFA date is coming up in 1Q14. Both products have orphan-drug status in the US.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.